Fox Run Management L.L.C. Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fox Run Management L.L.C. grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 149.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 23,290 shares of the biopharmaceutical company’s stock after acquiring an additional 13,966 shares during the quarter. Fox Run Management L.L.C.’s holdings in Celldex Therapeutics were worth $589,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CLDX. EverSource Wealth Advisors LLC raised its stake in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares in the last quarter. KBC Group NV grew its holdings in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. AlphaQuest LLC increased its position in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares in the last quarter. E Fund Management Co. Ltd. purchased a new stake in shares of Celldex Therapeutics in the 4th quarter valued at about $273,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at about $306,000.

Celldex Therapeutics Trading Up 5.8 %

Shares of CLDX opened at $20.78 on Tuesday. The firm has a market capitalization of $1.38 billion, a PE ratio of -8.09 and a beta of 1.76. The stock’s 50 day moving average is $22.15 and its two-hundred day moving average is $26.86. Celldex Therapeutics, Inc. has a twelve month low of $18.61 and a twelve month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CLDX shares. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday, February 28th. Morgan Stanley initiated coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 price target for the company. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. UBS Group began coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.